Table 2.

Unadjusted incidence rates and standardized cumulative incidences of hip fracture for dually-treated HIV/hepatitis B virus (HBV)-coinfected patients compared to treated HBV-monoinfected, antiretroviral therapy-treated HIV-monoinfected, and HIV/HBV-uninfected persons. Results exclude persons of Asian/Pacific Islander race.

	Population			Matched Sample
Cohort Comparison	No. Patients	No. Hip Fractures	Raw Hip Fracture Incidence Rate, Events/1,000 person-years (95% CI)	No. Patients	No. Hip Fractures	No. Deaths	Risk Of Hip Fracture at 5 Years (%)*	Additional Hip Fractures Per 1,000 Dually-Treated HIV/HBV Patients at 5 Years
Dually-Treated HIV/HBV	4,156	67	3.5 (2.7–4.4)	1,007	8	111	0.70†	4.3
Treated HBV	2,053	11	2.5 (1.2–4.4)	1,007	9	95	0.27
Dually-Treated HIV/HBV	4,156	67	3.5 (2.7–4.4)	4,155	67	649	1.70	4.6
Antiretroviral-Treated HIV	96,253	808	2.1 (2.0–2.3)	16,579	172	2,239	1.24
Dually-Treated HIV/HBV	4,156	67	3.5 (2.7–4.4)	4,150	67	646	1.64	4.2
Uninfected	746,794	11,580	4.5 (4.4–4.6)	16,522	273	1,454	1.22

Abbreviations: CI, confidence interval; HBV, hepatitis B virus; HIV, human immunodeficiency virus

^*Absolute risk of hip fracture was determined based on standardized cumulative incidences. Standardization to the characteristics of the coinfected patients was accomplished by weighting. Cumulative incidences were adjusted for competing risks. Differences in the cumulative incidences of coinfected patients arise from differences in the sample sizes as well as from having tenofovir as one of the standardizing characteristics for one of the models and not the others. See figures for additional details.

^†Because only a subset (n=1,007) of dually-treated HIV/HBV-coinfected patients were able to matched to treated HBV-monoinfected patients, the cumulative incidence of hip fracture for the coinfected cohort in this comparison differed from that of the other comparisons.